ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 676,35
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,85
-0,93%
Bitcoin
62 031,99
4,90%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Terns Pharmaceuticals Inc (TERN)

  7. Terns Pharmaceuticals Inc (TERN) Actualités

TERN Terns Pharmaceuticals Inc

5,39
0,10 (1,89%)
Dernière mise à jour : 21:44:08
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Terns Pharmaceuticals Inc TERN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,10 1,89% 5,39 21:44:08
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,39 5,21 5,57 5,29
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202422:05GLOBETerns Pharmaceuticals Announces Data from Ongoing Phase 1..
10/4/202422:05GLOBETerns Pharmaceuticals Appoints Melita Sun Jung as Chief..
14/3/202421:05GLOBETerns Pharmaceuticals Reports Fourth Quarter and Full Year..
11/3/202421:05GLOBETerns Pharmaceuticals Announces Orphan Drug Designation..
07/3/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
06/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:05GLOBETerns Pharmaceuticals to Participate in Upcoming March..
16/2/202400:02EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/2/202414:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:20EDGAR2Form 8-K - Current report
07/2/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New Chief..
07/2/202414:05GLOBETerns Pharmaceuticals Appoints Amy Burroughs as Chief..
02/2/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
26/1/202401:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:05GLOBETerns Pharmaceuticals to Highlight 2024 Priorities and..
03/1/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
29/11/202322:05GLOBETerns Pharmaceuticals to Present at the JMP Securities..
27/11/202322:05GLOBETerns Pharmaceuticals Mourns the Loss of Senthil Sundaram,..
14/11/202314:05GLOBETerns Pharmaceuticals Reports Third Quarter 2023 Financial..
13/11/202314:05GLOBETerns Pharmaceuticals Presents Late-Breaking Data from Phase..
09/11/202314:05GLOBETerns Pharmaceuticals to Participate in Upcoming November..
03/11/202321:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
02/11/202321:05GLOBETerns Pharmaceuticals Announces First Participant Dosed in..
19/10/202322:05GLOBETerns Pharmaceuticals to Participate in Upcoming Investor..
16/10/202314:05GLOBETerns Pharmaceuticals Announces Global Phase 1 Clinical..
10/10/202322:33EDGAR2Form 8-K - Current report
03/10/202322:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
06/9/202322:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
05/9/202322:05GLOBETerns Pharmaceuticals to Participate in Upcoming September..
08/8/202322:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:24EDGAR2Form 8-K - Current report
08/8/202322:15GLOBETerns Pharmaceuticals Reports Second Quarter 2023 Financial..
08/8/202322:05GLOBETerns Achieves Primary Endpoint and All Secondary Endpoints..
04/8/202300:00GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
03/8/202323:22EDGAR2Form 8-K - Current report
03/8/202323:05GLOBETerns Pharmaceuticals Announces Leadership Transition
18/7/202322:05GLOBETerns Pharmaceuticals to Host Virtual Key Opinion Leader..
05/7/202322:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
26/6/202322:05GLOBETerns Pharmaceuticals Highlights New Preclinical Data for..
06/6/202322:30GLOBETerns Pharmaceuticals to Present at Goldman Sachs 44th..
02/6/202322:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
25/5/202323:05GLOBETerns Pharmaceuticals Announces Publication of TERN-701..
24/5/202322:05GLOBETerns Pharmaceuticals to Present at Upcoming Investor..
22/5/202322:05GLOBETerns Pharmaceuticals to Highlight New Preclinical Data for..
15/5/202314:05GLOBETerns Pharmaceuticals Reports First Quarter 2023 Financial..
09/5/202322:05GLOBETerns Pharmaceuticals to Participate in the JMP Securities..

Dernières Valeurs Consultées

NASDAQ
TERN
Terns Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés